Life science company ValiRx plc (AIM: VAL) announced on Monday that it has entered into a comprehensive five-year agreement with the University of Dundee and its Drug Discovery Unit (DDU) to access research on novel therapeutic candidates. The first Evaluation Agreement focuses on pro-senescence, a promising area for treating various cancer types and diseases associated with healthy aging.
The Evaluation Agreement, spanning 12 months, will investigate a lead series of therapeutic candidates. The evaluation process will assess mechanism of action and anti-cancer activity at the Inaphaea BioLabs facility. If successful, the project may be considered for in-licensing on pre-agreed terms.
ValiRx focuses on early-stage cancer therapeutics and women's health. The company provides the framework for translating innovative science into clinical development, selecting and incubating promising drug candidates for further development and commercialisation.
The University of Dundee, a world-leading centre for life sciences research, ranks first in the Entrepreneurial Impact Ranking 2023. The Drug Discovery Unit, supported by the University's Research & Innovation Services, plays a key role in maximising research impact and strategic industry partnerships.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration